(2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((4-hydroxy-2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid

Catalog No. :
ACTJXH168
CAS No. :
24579-17-7
Molecular Formula :
C25H24O11
Molecular Weight :
500.46

IUPAC Name:(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-((4-hydroxy-2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid

(2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((4-hydroxy-2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(2S,3S,4S,5R,6S)-3,4,5-Trihydroxy-6-((4-hydroxy-2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
IUPAC Name(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-((4-hydroxy-2-oxo-3-(3-oxo-1-phenylbutyl)-2H-chromen-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
Molecular FormulaC25H24O11
Molecular Weight500.46
SMILESO[C@H]([C@H]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1OC2=CC=C(C(O3)=C2)C(O)=C(C(C4=CC=CC=C4)CC(C)=O)C3=O
InChI KeyHGQPQZDYDCOEEI-LWNSMTRGSA-N
Synonym7-Hydroxy Warfarin β-D-Glucuronide;4-Hydroxy-2-oxo-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-7-yl β-D-Glucopyranosiduronic Acid;β-D-Glucopyranosiduronic acid, 4-hydroxy-2-oxo-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-7-yl
CAS No.24579-17-7

Synthetic Route by SureRoute

1. ACTJXH168 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTJXH168 route product structure diagram
    ACTJXH16824579-17-7
Inquiry

2. ACTJXH168 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACTJXH168 route product structure diagram
    ACTJXH16824579-17-7
Inquiry

Comments (0)